Polaris Capital Management, LLC Supernus Pharmaceuticals, Inc. Transaction History
Polaris Capital Management, LLC
- $1.77 Billion
- Q4 2024
A detailed history of Polaris Capital Management, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Polaris Capital Management, LLC holds 47,000 shares of SUPN stock, worth $1.51 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
47,000
Previous 42,500
10.59%
Holding current value
$1.51 Million
Previous $1.33 Million
28.23%
% of portfolio
0.1%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$334 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$198 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$155 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$92.5 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$84.5 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...